Cargando…

History of fatigue in multiple sclerosis is associated with grey matter atrophy

Fatigue in multiple sclerosis (MS) has been associated with brain damage with low replicability. Temporal fatigue fluctuations have not been considered. We assessed whether sustained fatigue (SF) associates more strongly with grey matter (GM) changes than reversible fatigue (RF). Patients were strat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palotai, Miklos, Nazeri, Aria, Cavallari, Michele, Healy, Brian C., Glanz, Bonnie, Gold, Stefan M., Weiner, Howard L., Chitnis, Tanuja, Guttmann, Charles R. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791855/ https://www.ncbi.nlm.nih.gov/pubmed/31611598 http://dx.doi.org/10.1038/s41598-019-51110-2

Ejemplares similares

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis
por: Xia, Zongqi, et al.
Publicado: (2010)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Usability of a Mobile App for Real-Time Assessment of Fatigue and Related Symptoms in Patients With Multiple Sclerosis: Observational Study
por: Palotai, Miklos, et al.
Publicado: (2021)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
por: Bove, Riley, et al.
Publicado: (2013)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

Risk attitudes and risk perceptions in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2016)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course
por: Bove, Riley, et al.
Publicado: (2013)

Progression of regional grey matter atrophy in multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2018)

Grey matter atrophy in patients with benign multiple sclerosis
por: Niiranen, Marja, et al.
Publicado: (2022)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis
por: Meyer-Arndt, Lil, et al.
Publicado: (2020)

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
por: Rosso, Mattia, et al.
Publicado: (2020)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis()
por: Eshaghi, Arman, et al.
Publicado: (2014)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method
por: Popescu, Veronica, et al.
Publicado: (2016)

Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis
por: Makshakov, Gleb, et al.
Publicado: (2017)

Frontostriatal grey matter atrophy in amyotrophic lateral sclerosis A visual rating study
por: Radakovic, Ratko, et al.
Publicado: (2018)

Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references
por: de Sitter, Alexandra, et al.
Publicado: (2021)

Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity
por: Zhang, Tingting, et al.
Publicado: (2020)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort
por: de Sitter, Alexandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8ol9a1t6f29b1tv7bm0vgsduf5